For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.
Treatment Study for Patients with Non-Small Cell Lung Cancer, Melanoma or Colorectal Cancer
The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in patients with non-small cell lung cancer (NSCLC). Additionally the purpose of the study is to assess how effective entinostat and pembrolizumab are in combination in patients with NSCLC, melanoma, and mismatch-repair proficient colorectal cancer.
In order to participate you must meet the following criteria:
- Are 18 years of age or older.
- Have confirmed recurrent/metastatic NSCLC.
- Have a confirmed diagnosis of unresectable or metastatic melanoma.
- Have received at least one chemotherapeutic regimen in the advanced/metastatic setting for colorectal cancer.
This is a partial list of elgibility requirements.